Results from a combination study breathed life into the company's sitravatinib program.
News & Analysis: Mirati Therapeutics
MIrati Therapeutics, Iovance Biotherapeutics, and Personalis are all using genetic knowledge to help find cures for cancer.
Both biotechs are developing revolutionary new cancer drugs, but which stock is better for your portfolio right now?
It’s looking competitive in one cancer drug class.
This time, its own clinical trial is pushing the biotech higher.
This stock could soar at the end of the month, but is it worth the risk?
Due to the explosion in immuno-oncology in recent years, what was once a small scientific meeting near the end of the year has become a go-to event for drug developers.
Unfortunately, there were more of the latter.
Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.
These three biotech stocks should be outstanding long-term growth vehicles.